Is Compounded Semaglutide Still Legal? What the FDA Actually Says

Semaglutide and tirzepatide get treated as one topic in most coverage of compounding legality — same shortage story, same rules, just a different molecule. They are not the same story. The FDA resolved these two shortages roughly four months apart, litigated the resulting compounding fight in two different federal dockets, and closed the enforcement-discretion window on two different dates. The rules that applied once each shortage ended are the same rules — but "the same rules, applied on a different day" is not "the same situation," and treating them as interchangeable is how a lot of secondary coverage gets the semaglutide question wrong.

Here is what FDA's own record says about semaglutide specifically, read directly off the agency's site rather than carried over from what turned out to be true for tirzepatide.

The shortage that made compounding possible

Compounding pharmacies get narrow legal room to make a copy of a patented, FDA-approved drug under sections 503A and 503B of the Food, Drug and Cosmetic Act, and a national drug shortage is the biggest of those exceptions. While a brand-name drug sits on FDA's shortage list, both 503A pharmacies (compounding for one named patient) and 503B outsourcing facilities (compounding in batches) get room to fill the gap without that counting as an illegal copy of a commercial product¹.

Semaglutide — sold under the brand names Ozempic (type 2 diabetes) and Wegovy (chronic weight management) — had been on that shortage list since 2022, the same year tirzepatide joined it, driven by the same nationwide demand spike¹. That overlap is exactly why the two compounds get lumped together. What happened next didn't run on the same clock.

FDA's semaglutide timeline, read from the agency's own updates

• •February 21, 2025 — FDA determined the semaglutide injection shortage was resolved, based on the manufacturer's confirmed ability to meet national demand — the same kind of determination FDA had already made for tirzepatide, but four and a half months later². FDA gave 503A pharmacies until April 22, 2025, and 503B outsourcing facilities until May 22, 2025, before treating shortage-based compounding as a violation¹.
• •April 24, 2025 — a federal district court denied a preliminary injunction motion in Outsourcing Facilities Association v. FDA, 4:25-cv-00174 (N.D. Tex.) — a separately docketed case from the one that resolved tirzepatide's litigation. Per FDA's own update, that ruling meant 503A enforcement discretion for semaglutide "has ended" immediately; the 503B grace window continued to run through its already-scheduled May 22, 2025 end date, unaffected by the ruling¹.

That comparison is the finding most coverage skips: it isn't that semaglutide "went through the same thing" as tirzepatide. It went through the same kind of thing, on its own schedule, litigated in its own case. Tirzepatide's compounding industry lost its enforcement-discretion window on March 5, 2025. Semaglutide's kept running for another seven weeks, into late April.

What "the shortage is over" closes off for semaglutide

A 503A pharmacy can't compound a drug that's "essentially a copy" of a commercially available product — and once FDA calls a shortage resolved, semaglutide counts as commercially available again. FDA's own guidance treats a compounded drug as "essentially a copy" when it shares the approved product's active ingredient, a similar or substitutable strength, and the same route of administration, unless a prescriber documents that a specific change is clinically necessary for that individual patient¹.

503B facilities face the separate, narrower gate every outsourcing facility runs into once a shortage clears: they can compound from a bulk drug substance only if that substance sits on FDA's "503B bulks list," or the finished drug is currently on the shortage list. As of FDA's most recent update to this page, semaglutide is on neither list — the same dead end tirzepatide hit¹. The 503B pathway is closed for both compounds identically; that part genuinely is the same situation.

FDA does leave one narrow 503A allowance standing, and it isn't drug-specific: the agency says it doesn't currently intend to act against a pharmacy that fills four or fewer prescriptions of an essentially-a-copy compounded drug in a calendar month¹. That's a patient-specific safety valve, not a basis for a telehealth subscription business selling at scale.

The detail unique to semaglutide: the B12 question

One thing FDA's guidance addresses that has no real tirzepatide equivalent: a huge share of the compounded-GLP-1 market sells semaglutide combined with vitamin B12 (cyanocobalamin) — a common upsell across the telehealth providers on this site's own board. FDA's page directly addresses whether that combination counts as "essentially a copy" of the single-ingredient branded product, and says yes, under the same conditions as a single-ingredient product: same route of administration, and the semaglutide (and B12) amounts within 10% of the approved product's strength¹. Adding a second ingredient doesn't create a loophole around the essentially-a-copy test — FDA's guidance treats the combination the same way it treats plain compounded semaglutide, once the shortage that would have excused it is over.

What remains legal in 2026

Reading FDA's own conditions rather than a summary of them, compounded semaglutide stays on solid legal footing in a few specific situations, structurally identical to tirzepatide's:

• •A prescriber documents an individualized reason a specific patient needs a dose or formulation the commercial product doesn't offer.
• •A patient has a verified allergy or intolerance to an inactive ingredient in the commercial product.
• •A pharmacy stays under the four-prescriptions-per-month threshold for what would otherwise count as "essentially a copy."

What it doesn't cover, per the agency's own stated position, is bulk 503A or 503B compounding simply because it's cheaper than Ozempic or Wegovy, marketed at telehealth-subscription scale, with no individualized medical justification tied to a named patient — the same finding our tirzepatide legal breakdown already reached for that compound, reached independently here for this one.

The enforcement wave hit semaglutide claims too — not just tirzepatide's

FDA's February 20, 2026 action against 30 telehealth companies is already covered on this site's tirzepatide article, built around the Mounjaro/Zepbound language those letters cited. Re-reading six of those same letters today specifically for semaglutide content turned up something that article's own framing undersells: every one of them cites semaglutide claims with equal weight to the tirzepatide claims, not as an afterthought.

Strut Health's letter (MARCS-CMS 721448) cites the claim "Semaglutide is the active ingredient in the brand medications" as false or misleading in the identical sentence structure as its tirzepatide citation. BluefitMD's letter (MARCS-CMS 721446) is the most explicit of the six: it quotes BluefitMD's own site copy verbatim — "Compounded Semaglutide (the same active ingredient as Ozempic® and Wegovy®)" — right alongside the equivalent Mounjaro/Zepbound line, both cited as implying FDA approval that compounded drugs don't have³. Kin Meds, Viv Health, and Ivim Health each got the same mislabeled-compounder finding — a product label naming the telehealth company itself as the compounder, which none of them are — applied to their semaglutide products as directly as their tirzepatide ones. 24HrDoc's letter names Ozempic and Wegovy by brand, the same way it names Mounjaro and Zepbound: "Same ingredients as: Ozempic and Wegovy." MEDVi's letter (MARCS-CMS 721455, dated the same day as several of the letters above) applies the identical mislabeled-compounder finding to MEDVi's own semaglutide product labels. Direct Meds' letter (MARCS-CMS #716822, September 9, 2025) is the earliest-dated letter on this list, citing the claim "Compounded semaglutide contains the same active ingredient as branded semaglutide" as implying an FDA approval compounded drugs don't have — no close-out letter had been issued as of this review.

None of that changes which providers are legitimate — a provider genuinely operating inside one of the exceptions above is on solid ground regardless of which compound triggered a warning letter elsewhere on its site. What it means is that a reader treating "the tirzepatide warning letter" as a tirzepatide-only finding is missing that the same letter, for these six companies, is just as much a semaglutide finding.

The freshest finding: a June 2026 letter this board's own review caught

Checking FDA's warning letter database for semaglutide specifically — rather than starting from the roster the tirzepatide article had already assembled — surfaced something newer: on June 8, 2026, FDA issued a warning letter to Eden Health International Inc., dba Eden (MARCS-CMS 728279), a provider reviewed on this board⁴. It's a different violation than the February wave's pattern. FDA's review of Eden's site in March 2026 found two issues: a compounded-product label identifying "Eden" as the compounder (it isn't, the same mislabeling issue the February letters cited), and a separate claim that Eden's compounded products are "sourced from FDA-licensed 503(a) outsourcing facilities" — which FDA calls false and misleading on its own terms, because compounding pharmacies and outsourcing facilities are never "FDA-approved" or "FDA-licensed" entities; no such designation exists under the FD&C Act for either one⁴. The letter names both semaglutide and tirzepatide products on Eden's site, not just one.

This is the newest FDA enforcement action against a compounded-GLP-1 telehealth provider this site has found on either compound — three and a half months after the February wave, and not part of it. It's a reminder that this is a moving target: a provider's legal standing on the day this article was checked isn't a permanent grade, and re-checking FDA's own database periodically, rather than trusting a summary written months earlier, is how a finding like this one gets caught at all.

How this differs from tirzepatide's situation, in practice

Reading the two records side by side rather than assuming they match:

• •Same shortage story, different resolution dates. Both compounds were declared shortage-resolved in the same general wave of GLP-1 supply stabilizing — tirzepatide first (October 2024, reaffirmed December 2024), semaglutide four and a half months later (February 2025).
• •Same legal fight, two different dockets. Both went through Outsourcing Facilities Association v. FDA litigation, but as two separately filed and separately decided cases — 4:24-cv-00953 for tirzepatide, 4:25-cv-00174 for semaglutide — with courts ruling seven weeks apart.
• •Same current dead end for 503B. Neither compound sits on the 503B bulks list or the shortage list today, so the batch-compounding pathway is equally closed for both.
• •Semaglutide carries one wrinkle tirzepatide's article doesn't need: the B12-combination guidance, relevant to a large share of what this board's own providers actually sell.
• •The enforcement record runs in parallel, not separately — the same companies, the same letters, cite both compounds together, and the newest action found (Eden, June 2026) targets both compounds in the same letter rather than singling one out.

Why this matters when you're comparing providers

None of this makes every compounding pharmacy selling semaglutide "illegal" — a provider genuinely operating inside one of the exceptions above is on solid ground, the same as any tirzepatide provider in the same position. What it means is that "compounded" and "cheap" stopped being evidence of a clever workaround once the shortage that justified scale compounding closed, on this compound just as much as tirzepatide's — and a provider whose intake never asks why a compounded dose is medically necessary for you isn't obviously operating inside the exception FDA left open.

Six providers added to this board most recently make the point concretely. Bodybuilding Health+ fronts its semaglutide price with a "first month" figure roughly 40% below the "regular price" printed on the same page. HealthSource bills semaglutide "every 4 weeks" rather than monthly, a cadence its own Terms of Use never mention. PepHaūs is the only one of the six to name a specific pharmacy (Greenwich Rx) AND state a 503A category on the same page — but publishes no state list anywhere. Rylo Health fronts its lowest semaglutide price with a live "First 20 members only" scarcity counter. Vytora Health discloses its true standing semaglutide rate directly, but its named fulfillment pharmacy turns out to be a shared vendor also used by a direct competitor on the same board. Yucca Health states its real month-to-month semaglutide price directly beside its discounted prepay rate — an honest disclosure most peers skip — though its own Terms disclose that renewals process 5-7 days early. That's a pharmacy-sourcing and price-transparency question as much as a legal one, which is exactly why our semaglutide provider comparison reads pharmacy disclosures directly off each provider's own site instead of assuming "compounded" means the same thing everywhere. Once a prescriber has actually given you a dose in milligrams, our reconstitution calculator hub converts that into the syringe volume and units it corresponds to — arithmetic on the number your prescriber gave you, not a suggestion of what that number should be.

A second batch of six added to the board the same week shows the same pattern from a different angle. PreventiveMD publishes the fullest pricing table on the board — every plan tier shown together — yet its own sitewide headline still quotes only the cheapest, 12-month-prepay figure. The same 503A pharmacies fill PreventiveMD's Glutathione protocol too, priced the same "all-in" way ("As low as $94/mo, all-in") — see our Glutathione provider comparison for how that separate compound's pricing and disclosure holds up across this board's roster. TelePeptide discloses its true no-commitment rate directly beside every prepay tier, but names no pharmacy at all. Vyora Wellness advertises a flat "monthly" price that its own Refund Policy admits bills every three weeks. REMEVi names four fulfillment pharmacies directly, yet its own pages disagree with each other on whether the medication is 503A or 503B. RxPepsDirect sells no subscription at all — a dose-scaling vial price plus a per-visit fee — but states plainly it can't refund or answer for the medication charge itself. YourHealthRx discloses a real first-month promo on its own product pages, then quotes that same promo number as the standing price on its own homepage. Two more added the same week round out the pattern from opposite ends: Trimi names two specific 503A pharmacies directly on its own FAQ page, clearing the pharmacy bar cleanly, but headlines a 12-month prepay rate that is 88% below its own disclosed no-commitment monthly price; Oak states an explicit "One price · All dosages · No subscriptions" claim next to its headline semaglutide price, one of the cleanest no-commitment claims on this board, but names no pharmacy at all anywhere on its site. Three more added the following week extend the pattern into WLR's Tier 2 candidate list: Alternate Health Club prices semaglutide at a genuinely flat $129/mo, confirmed against its own shop, but its own Terms & Conditions name two different states' law for two different sections of the same document. AquaVita NextGen is the online storefront of a real, physical medspa (independently verified via its own Google Maps and Yelp listings) with disclosed one-month and three-month semaglutide pricing shown side by side — but no Terms of Service, Privacy Policy, or Refund Policy exists anywhere on the live site, a gap this board's other 41 providers all clear in some form. Belle Health names four pharmacy partners directly and a clean all-50-states claim, and its own semaglutide price agrees across both of its own pages at $119/mo — the one product on Belle's own roster where its pricing doesn't contradict itself (its tirzepatide listing, reviewed on the sibling board, does). Two more added from a second round of Katalys partner research round out the pattern one more way: Care Bare Rx names both oral and injectable semaglutide directly on its own product page and states a 503A category for its 4-pharmacy network — but two of those four named pharmacies carry real FDA warning letters. Telos Rx's own review covers a provider that names its primary pharmacy directly with a sourced 503A statement and discloses a genuinely specific 10-state exclusion list — but its own "as low as $99" headline sits beside a $299 "compare" price the site never confirms is an actual 1-month rate. Two more, re-verified live after an earlier automated pass mischaracterized both: Breeze Meds names "Semaglutide Injection" directly in its own navigation menu — a real, distinct product, not the generic "GLP-1" label an earlier pass mistook for silence — but its own homepage publishes only a category-wide "Starting at $199" price, gated behind an intake quiz before a compound-specific figure appears. MangoRx sells "Slim," an oral semaglutide tablet, at a flat, explicitly "price locked in" $299/month with no hidden fees — but names its compounding pharmacy only by accreditation (Texas-based, URAC and ACHC-PCAB certified), never by company name. One more, verified live by completing its own checkout funnel through the real plan-selection screen rather than reading marketing copy: Gala Health shows a genuine $299/month semaglutide Monthly (no-commitment) sticker price, but headlines a "$179 LIMITED OFFER" first-shipment price gated behind a fake-scarcity "Only 24 discounts left" counter and a countdown timer — the exact same $179 figure it also shows for tirzepatide, despite that drug's real $399/month rate, meaning the number isn't tied to either drug's actual cost at all. One more, from a continuation of that same Tier 2 research round: Big Easy Weight Loss names six pharmacy partners individually, each with its own stated 503(a)/503(b) category and its own state-exclusion list — the most granular per-pharmacy disclosure found in this whole research round — but its own semaglutide product page never states a monthly price at all, only a "$495 / 12 week plan" package total, with a same-page new-patient discount toggle down to $399 and "installment pricing" offered only as financing, never as a lower recurring rate. One more shows the same shape from a cleaner starting point: Cora Health names two specific 503A pharmacies by name (Hallandale Pharmacy, VialsRx) and discloses all four of its own pricing tiers side by side on one /plans page, labeled by billing cadence — genuinely transparent structure — but its own homepage and page metadata still headline the 12-month-prepay figure ("$99/month") in most placements without the "annual" qualifier attached, while the real no-commitment "billed monthly" rate, stated two clicks away, is $175/month, 77% higher. One more takes transparency a step further, in words if not in headline placement: Ondra Health is the only provider in this whole research round whose own pricing page states its prepay mechanism outright, in plain words — "The lowest per-month prices reflect the 6- and 12-month plans, billed in full up front" — yet its homepage hero still headlines that same lowest figure ("From $96/mo") rather than the $149/month no-commitment rate its own pricing table discloses two sections down. One more shows what the cleanest version of this disclosure looks like: OrderlyMeds states its new-patient promo ("$74/mo $149 for 2 months," explicitly labeled a new-customer special) directly beside a separate "Monthly plans... $149" line with no promo language attached, both on the same /pricing page — but its own FAQ names its three fulfillment pharmacies and its 503A claim in two separate sentences, never tying a specific pharmacy to that category by name. One more names its pharmacies AND their category in a single sentence, the cleanest same-citation match found this round: Tryozi states directly, "Licensed U.S. 503A compounding pharmacies: RedRock, Health Warehouse, Precision Medicine, Triad Rx" — but its featured homepage price ("$139") is explicitly a first-4-weeks-only discount shown on the same line as the real standing rate, $279/month, exactly double. One more shows a genuinely flat price undercut by a different kind of gap: DrMedHealth repeats "$199/month" for semaglutide identically across its homepage and FAQ with no "starting at" qualifier — but that same homepage states "Available in All 50 States" in one section and "All 50 US states plus Washington DC" in its own FAQ answer just below it, a live self-contradiction on a single page. Eight more, from a later Katalys research round re-verified live rather than trusted from the research doc: altRx states a company-wide, unhedged 503A claim directly in its Terms of Service — but its own product card shows "Starting at $199/mo $89/mo," the featured $89 struck through against the real reference rate, confirmed a promotion (not a standing price) by its own coupon-code system. Jently names its pharmacy AND its 503A category in one sentence and discloses its real "MONTHLY RETAIL PRICE" ($199) on the same page as its prepay tiers — a transparent same-page disclosure. FitFlow shows "$99 $74 per month Limited time only" for semaglutide, a struck-through reference price beside an explicitly time-limited promotion on the same card. GobyMeds states a clean "Starting at $99/m" that checks out against its own bundle math, undercut by a sitewide promo banner naming an offer end-date that had already passed. Mochi Health genuinely does bill $79/month as a standing membership fee, but that fee explicitly excludes the medication itself — semaglutide is priced separately, starting at $99/month more. TrimRx prices semaglutide "Starting at $179," mined directly from its own compiled site bundle since a plain fetch renders an empty shell — but an order becomes non-refundable the moment intake is submitted. ReadyRx silently auto-applies a discount coupon to every visitor by default; the true standing $249/month rate was confirmed only by querying its own live pricing API directly. RxION Health discloses a genuinely transparent 1-month/prepay menu (a 6-month tier as low as $99/mo) on the same page — but its LegitScript badge links to a generic keyword search rather than a checkable seal. Eight more, from the next wiring batch, re-verified live rather than trusted from the research doc: PepScribe names four 503A pharmacies directly on its own /pharmacy-partners page, more specific than most peers — but publishes only an undifferentiated $159-$548 range across every therapy, with no semaglutide-specific price found. Direct GLP1 prices semaglutide "From $85/mo," but a mandatory $89/month membership fee is required on top to purchase anything at all, for a true floor of $174/mo. Lemonaid Health states its $299/month semaglutide price and its $49/month membership fee together, on the same page, for a $348/month combined cost disclosed together rather than hidden. SkinnyRx confirms a real $199/mo semaglutide price and an unhedged 503A claim — but only via a Googlebot user agent, since a plain fetch of its own SPA returns an empty shell. Blue Haven Rx states, "a flat $179/month for semaglutide... no additional fees" — an unusually clean claim, undercut by its own pharmacy-category phrase, "503A Outsourcing Facilities," which mixes two different FDA terms. Momentum Health 360 defaults its semaglutide checkout to a "Starter" tier ($250) that requires a hidden 2-month prepay — the true walk-away-anytime price is its "Maintenance" tier, $325/mo, 30% higher. Join Josie sells compounded semaglutide too, but its price was not independently broken out with this board's usual rigor this pass, so only its tirzepatide listing is ranked; its own FAQ discloses the same 12-month-headline mechanism either way. Embody sells compounded semaglutide at a real $299/mo, alongside the same sale-price-vs-standing-rate gap already documented for its tirzepatide listing — a "$79/mo" figure blasted across the homepage that is a Sale price, not the standing rate. Four more, from WLR's Tier 2 candidate list continued: Bionomy Health prices semaglutide at a flat, unhedged $189/mo with a genuinely no-lock-in billing model, but one of its two named fulfillment pharmacies, Strive Pharmacy, has its own real FDA warning letter. CLYR Health prices semaglutide at a flat $169/mo — cleaner than its own tirzepatide listing's 8-week billing-cycle mismatch — but its own homepage states three different, unreconciled numbers for state coverage in three different sections. He & She MD headlines "$139 to start" for semaglutide injection, but its own footnote, on the same page, discloses the plan renews at $199/month after 6 months, a 43% jump — the same shape repeats for its oral semaglutide SKU. Elara Health and Wellness labels its "$183/mo" semaglutide figure an "annual plan" rate — the same framing its own dedicated tirzepatide page confirms means a full year prepaid, not a monthly commitment. Three more, from a continuation of that same Tier 2 research round: Luma Meds sells all three of this site's tracked compounds from one company, but its own pricing table's raw HTML shows a "3-Month Plan" row labeled "$50 OFF" for a real $329/mo gap on semaglutide, not $50. MaxLife headlines "Starting at $155/mo" for semaglutide, but its own dedicated /semaglutide page discloses that figure is a first-month or 3-month-prepay rate — the true standing price is $195/mo — and MaxLife itself received its own FDA warning letter (MARCS-CMS 721453, February 20, 2026) from the same February sweep documented above. NewSelf prices Semaglutide+ at a flat $134.99/month across every dose, but headlines a separate "As Low As $99.97" figure with no disclosed mechanism anywhere on the site, and NewSelf itself received its own FDA warning letter (MARCS-CMS 721472, February 20, 2026) the same day. Five more, from a continuation of that same Tier 2 research round: RxPros states "$99.99 A Month" for semaglutide at the top of its homepage, captioned "No Membership Costs" — but its own comparison table further down the same page discloses that identical figure is actually "(Paid Annually)," not a flat monthly rate. Zera Health sells all three of this site's tracked compounds from one company and names Strive Pharmacy directly, but its own promotional price chip for semaglutide doesn't match either figure in its own pricing table further down the same page, and its refund policy allows none except for medical disqualification. Peak Wellness discloses its standing $249/mo semaglutide rate directly beside its $179 first-month rate — genuinely transparent — but its own Terms & Conditions allow charging a renewal up to three days before the stated billing date. SnagRx headlines "Locked-In Flat Pricing for Life" for semaglutide directly beside a live countdown badge (frozen at zero) claiming the price is about to increase — a self-contradictory claim on the same page. RestorLife Med sells all three of this site's tracked compounds from one company with a named founding physician, but its own homepage FAQ claims "all 50 states" while its own Terms of Use say coverage is limited to "certain states" only — two of its own pages disagree. Three more, from the next round into WLR's Tier 3 candidate list: Nova MD prices semaglutide at a flat, fully disclosed $175/mo with no promo-vs-standing gap to dig for, but once an order reaches the pharmacy, its own Refund Policy locks cancellation and refunds for 10 days even if the package hasn't shipped. Neo Soma Healthcare discloses its semaglutide price plainly ("$99 for your first month, $199/month thereafter"), but its own Terms of Service state the site is "not tailored to comply with" HIPAA or FISMA, and its own Refund Policy allows no refund under any circumstance. Maves prices semaglutide at a disclosed $199/mo standing rate and carries a genuinely verified LegitScript seal, but its own Terms of Service use the identical 28-30-day, non-refundable Membership Fee language already found on RestorLife Med above. Four more, from a continuation of that same Tier 3 research round: HealthRX discloses semaglutide pricing in a structured table across four plan lengths ($190/mo, 1-month plan) and states a direct 503A claim, but no legal entity name is disclosed anywhere on the site. Zappy Health names its compounding pharmacy directly ("The Pharmacy Hub"), but its own homepage headline ("From $159/mo") is a first-time-only prepay pack — the real billed-monthly rate, disclosed on the same page, is $249/mo — and it carries its own FDA warning letter (MARCS-CMS 717991, February 20, 2026). SkyRx prices semaglutide at a flat $199/mo with a direct 503B claim, but its own FAQ and pricing section contradict each other on whether tirzepatide — a different compound — is actually available yet. Aurelius Health Group sells a named microdose tirzepatide protocol, not semaglutide — checked and confirmed not to sell this specific compound anywhere on its site, so it is not ranked on this board at all. Nuform Health sells a "GLP Vitamin Blend" described as compounded, but never names semaglutide specifically as the active ingredient anywhere on the site — ranked only on the sermorelin board, the one compound its own site names by name. Six more, from the next round into WLR's Tier 3 candidate list continued, rendered fully only via Chrome: Ozari Health names two specific 503A pharmacies directly and discloses a real Month-to-Month standing rate ($175/mo) right beside its first-time-only 3-Month Starter promo ("from $86/mo") on the same page — but one of those two pharmacies, Hallandale Pharmacy, carries a real FDA warning letter closed out by FDA in 2022. Näky discloses a real, disclosed 1/3/6-month semaglutide price ladder inside a collapsed "Pricing Details" accordion a plain fetch never reaches — its own homepage headline ("starting at $145/mo") is the deepest, 6-month-prepay tier of that same ladder, and its own Refund Policy rules out any refund of a charged fee. Citizen Meds prices semaglutide at a rare, cleanly-labeled one-time $125 — "no subscription necessary" — with a cheaper optional auto-refill disclosed on the same page, but no legal entity name is disclosed anywhere on the site and its own Refund Policy is a flat, unhedged "no refund policy." Corsica Health discloses both a "1 Month Plan" standing rate ($249/mo) and a labeled "3 Month Plan" discount side by side on the same semaglutide product page — genuinely transparent — but its own Terms & Conditions rule out any refund of consult fees and state "all sales are final." Fitish RX prices compounded Semaglutide + B6 at a genuinely flat "$219... Regular price," no promo-vs-standing gap to decode, but FDA issued the company a warning letter (MARCS-CMS 728280, June 8, 2026) — the most recent letter on this list — over the same mislabeled-compounder claims documented for several peers above. Remi Meds discloses a clean, dose-tiered semaglutide price ladder ($249-$369/mo, rising with dose as expected), but no legal entity name is disclosed anywhere on the site — its own Terms and Conditions name only a third-party arbitration administrator, never Remi Meds' own entity. Same exception, same enforcement record, forty more providers to read the same way rather than take at face value.